Allogene Therapeutics, Inc. (ALLO) has declined by 32.73% in aftermarket – What’s going on?
Allogene Therapeutics, Inc. (ALLO) has seen a decrease of 32.73% in the aftermarket when the company reported FDA Clinical Hold of AlloCAR Trials. However, the last trading session closed at $24.38 with an increase of 1.71. ALLO Reports FDA Clinical Hold of AlloCAR Trials Based on a Single Patient Case in ALPHA2 Trial On 7th […]